Pollinex Quattro Tree: Allergy vaccine

ArticleinExpert opinion on biological therapy 9(3):377-82 · April 2009with24 Reads
DOI: 10.1517/14712590802699596 · Source: PubMed
Abstract
An overview of short-term specific immunotherapy (ST-SIT) highlighting Pollinex Quattro (PQ) Tree is presented. The product development of this novel allergy vaccine using modifying agent glutaraldehyde, adjuvant monophosphoryl lipid and L-tyrosine have heralded a superior ST-SIT. Since 1999 when PQ was founded in Germany, various research trials assessing both the standardization and clinical studies have been done. A review of these studies demonstrates the efficacy and safety of PQ Tree in both pediatric and adult trials. The uniqueness of this product allows a shorter course of four pre-seasonal injections to provide control of allergy symptomatology in seasonal rhinitis patients. The PQ Tree product studies show a similar efficacy and safety profile to the grass formulation trial.
    • "Glutaraldehyde modified allergenic extracts (allergoids) from grass, tree and ragweed pollens have reduced IgE reactivity, but maintain IgG reactivity[34]and are readily adsorbed to the microcrystalline tyrosine (MCT) in modified allergen tyrosine adsorbed (MATA) formulations. Clinical studies have shown that the addition of MPL® to MATA allergy immunotherapy formulations provides a more effective treatment for IgE mediated allergy353637383940. The contribution of electrostatic, hydrophobic and ligand exchange binding forces between antigens and aluminium adjuvants has been investigated by the addition of ethylene glycol and ionic species[41,42]. "
    [Show abstract] [Hide abstract] ABSTRACT: Infectious disease vaccine potency is affected by antigen adjuvant adsorption. WHO and EMA guidelines recommend limits and experimental monitoring of adsorption in vaccines and allergy immunotherapies. Adsorbed allergoids and MPL® in MATA-MPL allergy immunotherapy formulations effectively treat IgE mitigated allergy. Understanding vaccine antigen adjuvant adsorption allows optimisation of potency and should be seen as good practice; however current understanding is seldom applied to allergy immunotherapies. The allergoid and MPL® adsorption to MCT in MATA-MPL allergy immunotherapy formulations was experimental determination using specific allergen IgE allerginicity and MPL® content methods. Binding forces between MPL® and MCT were investigated by competition binding experiments. MATA-MPL samples with different allergoids gave results within 100-104% of the theoretical 50μg/mL MPL® content. Unmodified drug substance samples showed significant desirable IgE antigenicity, 1040-170QAU/mL. MATA-MPL supernatant samples with different allergoids gave results of ≤2μg/mL MPL® and ≤0.1-1.4QAU/mL IgE antigenicity, demonstrating approximately ≥96 & 99% adsorption respectively. Allergoid and MPL® adsorption in different MATA-MPL allergy immunotherapy formulations is consistent and meets guideline recommendations. MCT formulations treated to disrupt electrostatic, hydrophobic and ligand exchange interactions, gave an MPL® content of ≤2μg/mL in supernatant samples. MCT formulations treated to disrupt aromatic interactions, gave an MPL® content of 73-92μg/mL in supernatant samples. MPL® adsorption to l-tyrosine in MCT formulations is based on interactions between the 2-deoxy-2-aminoglucose backbone on MPL® and aromatic ring of l-tyrosine in MCT, such as C-H⋯π interaction. MCT could be an alternative adjuvant depot for some infectious disease antigens. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Aug 2015
    • "Monophosphoryl lipid A, a derivative of lipid A from Salmonella Minnesota R595 lipopolysaccharide , is a TLR-4 agonist. Pollinex Quattro vaccines combine chemically modified grass, ragweed, or tree allergens with monophosphoryl lipid A [39]. Clinical trials in adults and children have shown symptom improvement404142. "
    [Show abstract] [Hide abstract] ABSTRACT: This article reviews the literature on allergen modifications and novel routes of delivery for antigen-specific immunotherapy for allergic disease. Allergen modifications include the use of recombinant proteins, combining antigens with infectious carrier proteins, peptide immunotherapy, and genetic vaccines containing the code for allergenic proteins. Novel routes of delivery include oral immunotherapy, intralymphatic immunotherapy, epicutaneous immunotherapy, and oral mucosal immunotherapy. Allergen depot preparations, such as biodegradable, injectable microspheres and sublingual tablets, have also been developed. Current research in immunotherapy for allergic disease has focused on improving efficacy and patient adherence to therapy, while minimizing the risks of serious adverse events.
    Article · Jun 2013
    • "In addition, after therapy, skin-prick test reactivity was significantly reduced and pollen-specific IgG was significantly increased, whereas pollen-specific IgE was unchanged. Larger therapeutic trials were conducted in both pediatric and adult patients with allergic rhinitis, allergic conjunctivitis, and asthma caused by grasses, trees, or ragweed [32, 33]. Skin-prick test reactions and the seasonal allergen-induced rise of IgE were significantly reduced with Pollinex® treatment, while elevating allergen-specific IgG levels [33]. "
    [Show abstract] [Hide abstract] ABSTRACT: Allergic diseases affect millions of adults and children in the United States. Allergen immunotherapy has been a treatment option for diseases such as allergic rhinitis, allergic asthma, and venom allergy for the last 100 years. In the last 25 years, alternative approaches to traditional subcutaneous immunotherapy have been developed. The purpose of these new therapies is two-fold: to improve safety and to improve the efficacy of allergen immunotherapy. Aluminum hydroxide has been used as an adjuvant to standard immunotherapy, but due to concerns about side effects, its use has been decreasing. The modification of allergens into allergoids has been an effective therapy in Europe, but at this time no preparations are available for use in the United States. Toll-like receptors have demonstrated mixed results with early trials in the United States, showing promise with the use of a TLR4 agonist, while a TLR9 agonist had disappointing results. Early studies with the use of virus-like particles with and without allergens have shown additional promise, and further trials are currently underway. These novel approaches may improve the immunologic response and often the clinical outcomes for the management of allergic diseases.
    Article · Mar 2013
Show more